SLEEP 2026 | Orexin agonists in narcolepsy: trial findings, subtype differences, and biomarker-guided therapy

Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, discusses the Phase III data for oveporexton, an orexin receptor 2 agonist that has demonstrated significant improvements in excessive daytime sleepiness, wakefulness, and cataplexy in patients with narcolepsy type 1. She explores the potential implications of these findings for narcolepsy type 2 and highlights the growing importance of assessing orexin deficiency as a biomarker to guide treatment decisions in central disorders of hypersomnolence. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) congress in Baltimore, MD.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.